Analytical Data
-
Gene name
CATHL4
- Application
-
Alternative Names
CATHL4；Cathelicidin-4
-
Species
Bovine
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P33046
-
Expression Region
131-143aa
-
AA Sequence
ILPWKWPWWPWRR
-
Molecular Weight
17.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CATHL4, or Cationic Antimicrobial Peptide H4, is a member of the cathelicidin family of antimicrobial peptides known for their crucial role in the innate immune response. These peptides are primarily expressed in various tissues and are recognized for their antimicrobial, anti-inflammatory, and wound-healing properties. Research into CATHL4 has garnered attention due to its potential applications in combating antimicrobial resistance, a growing global health crisis where conventional antibiotics are becoming increasingly ineffective against certain pathogens. Studies have indicated that CATHL4 possesses broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, and even some viruses. Additionally, its ability to modulate immune responses makes it a candidate for therapeutic applications beyond antimicrobial use, such as in conditions characterized by excessive inflammation or impaired healing. The recombinant expression of CATHL4 allows for a more accessible study of its properties and facilitates the potential development of novel therapeutic agents. Understanding the mechanisms of action, structure-activity relationships, and the potential of CATHL4 can pave the way for innovative treatments in infectious diseases and inflammatory disorders, thus addressing critical unmet medical needs.
